<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hu, Guoqing</style></author><author><style face="normal" font="default" size="100%">Fu, Qiang</style></author><author><style face="normal" font="default" size="100%">Jin, Maolin</style></author><author><style face="normal" font="default" size="100%">Li, Jie</style></author><author><style face="normal" font="default" size="100%">Pan, Liangxi</style></author><author><style face="normal" font="default" size="100%">Bai, Yuxian</style></author><author><style face="normal" font="default" size="100%">Wang, Huaijin</style></author><author><style face="normal" font="default" size="100%">Zhang, Jianwei</style></author><author><style face="normal" font="default" size="100%">Yu, Ding</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Clinical Research on Use of Oxaliplatin in Combination with HCPT, LV and 5FU in a Regimen for Advanced Gastric Cancer</style></title><secondary-title><style face="normal" font="default" size="100%">Chinese Journal of Clinical Oncology</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2004</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2004-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">336-341</style></pages><volume><style face="normal" font="default" size="100%">1</style></volume><issue><style face="normal" font="default" size="100%">5</style></issue><abstract><style  face="normal" font="default" size="100%">OBJECTIVE To observe the effects and adverse reactions of a OXA-HCPT LV/5FU 3 regimen for patients with advanced gastric cancer.METHODS OHLF 3 regimen: OXA 130 mg/m2iv d 1, HCPT 6 mg / m2, iv d 1~5, LV 200 mg/m2iv 2 h followed by a 5FU 400 mg/m2 iv bolus and 5FU 600 mg/m2 iv d 1-3, were given, every 21 days as 1 cycle. Assessment of the tumor was conducted after 3 cycles and the effective cases were confirmed after 4 weeks.RESULTS Among 39 patients, 36 were actually evaluable. Overall response rates (CR + PR) were 50%; the major adverse reactions were mild hematological toxicity, nausea and vomiting and peripheral nerve abnormalities.CONCLUSION The OHLF 3 regimen using OXA and HCPT Is effective and results in mild toxicity when used In combined chemotherapy for advanced gastric cancer.</style></abstract></record></records></xml>